<?xml version="1.0" encoding="UTF-8"?>
<billStatus>
  <bill>
    <relatedBills />
    <updateDate>2018-11-21T21:23:05Z</updateDate>
    <committeeReports />
    <billNumber>1576</billNumber>
    <title>Generic Complex Drugs Safety and Effectiveness for Patients Act of 2015</title>
    <recordedVotes />
    <actions>
      <item>
        <actionDate>2015-03-27</actionDate>
        <committee>
          <name>Health Subcommittee</name>
          <systemCode>hsif14</systemCode>
        </committee>
        <links />
        <sourceSystem>
          <name>House committee actions</name>
          <code>1</code>
        </sourceSystem>
        <text>Referred to the Subcommittee on Health.</text>
        <type>Committee</type>
      </item>
      <item>
        <type>IntroReferral</type>
        <text>Referred to the House Committee on Energy and Commerce.</text>
        <committee>
          <name>Energy and Commerce Committee</name>
          <systemCode>hsif00</systemCode>
        </committee>
        <links />
        <sourceSystem>
          <name>House floor actions</name>
          <code>2</code>
        </sourceSystem>
        <actionCode>H11100</actionCode>
        <actionDate>2015-03-24</actionDate>
      </item>
      <item>
        <type>IntroReferral</type>
        <text>Introduced in House</text>
        <committee />
        <links />
        <sourceSystem>
          <name>Library of Congress</name>
          <code>9</code>
        </sourceSystem>
        <actionCode>Intro-H</actionCode>
        <actionDate>2015-03-24</actionDate>
      </item>
      <item>
        <type>IntroReferral</type>
        <text>Introduced in House</text>
        <committee />
        <links />
        <sourceSystem>
          <name>Library of Congress</name>
          <code>9</code>
        </sourceSystem>
        <actionCode>1000</actionCode>
        <actionDate>2015-03-24</actionDate>
      </item>
      <actionByCounts>
        <houseOfRepresentatives>4</houseOfRepresentatives>
      </actionByCounts>
      <actionTypeCounts>
        <placeholderTextForH>1</placeholderTextForH>
        <introducedInTheHouse>1</introducedInTheHouse>
        <billReferrals>1</billReferrals>
        <introducedInHouse>1</introducedInHouse>
      </actionTypeCounts>
    </actions>
    <sponsors>
      <item>
        <state>TX</state>
        <identifiers>
          <gpoId>8182</gpoId>
          <lisID>1751</lisID>
          <bioguideId>B001248</bioguideId>
        </identifiers>
        <middleName>C.</middleName>
        <fullName>Rep. Burgess, Michael C. [R-TX-26]</fullName>
        <bioguideId>B001248</bioguideId>
        <party>R</party>
        <district>26</district>
        <lastName>Burgess</lastName>
        <byRequestType />
        <firstName>Michael</firstName>
      </item>
    </sponsors>
    <committees>
      <billCommittees>
        <item>
          <activities>
            <item>
              <name>Referred to</name>
              <date>2015-03-24T13:06:35Z</date>
            </item>
          </activities>
          <name>Energy and Commerce Committee</name>
          <chamber>House</chamber>
          <systemCode>hsif00</systemCode>
          <subcommittees>
            <item>
              <activities>
                <item>
                  <name>Referred to</name>
                  <date>2015-03-27T20:30:39Z</date>
                </item>
              </activities>
              <name>Health Subcommittee</name>
              <systemCode>hsif14</systemCode>
            </item>
          </subcommittees>
          <type>Standing</type>
        </item>
      </billCommittees>
    </committees>
    <billType>HR</billType>
    <introducedDate>2015-03-24</introducedDate>
    <calendarNumbers />
    <cosponsors>
      <item>
        <state>NC</state>
        <district>1</district>
        <party>D</party>
        <sponsorshipWithdrawnDate />
        <identifiers>
          <gpoId>8024</gpoId>
          <lisID>1761</lisID>
          <bioguideId>B001251</bioguideId>
        </identifiers>
        <middleName />
        <fullName>Rep. Butterfield, G. K. [D-NC-1]</fullName>
        <bioguideId>B001251</bioguideId>
        <sponsorshipDate>2015-03-24</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
        <lastName>Butterfield</lastName>
        <firstName>G. K.</firstName>
      </item>
      <item>
        <state>NE</state>
        <district>2</district>
        <party>D</party>
        <sponsorshipWithdrawnDate />
        <identifiers>
          <bioguideId>A000373</bioguideId>
          <lisID>2257</lisID>
          <gpoId />
        </identifiers>
        <middleName />
        <fullName>Rep. Ashford, Brad [D-NE-2]</fullName>
        <bioguideId>A000373</bioguideId>
        <sponsorshipDate>2015-03-24</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
        <lastName>Ashford</lastName>
        <firstName>Brad</firstName>
      </item>
      <item>
        <state>FL</state>
        <district>12</district>
        <party>R</party>
        <sponsorshipWithdrawnDate />
        <identifiers>
          <bioguideId>B001257</bioguideId>
          <lisID>1838</lisID>
          <gpoId>7881</gpoId>
        </identifiers>
        <middleName>M.</middleName>
        <fullName>Rep. Bilirakis, Gus M. [R-FL-12]</fullName>
        <bioguideId>B001257</bioguideId>
        <sponsorshipDate>2015-03-24</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
        <lastName>Bilirakis</lastName>
        <firstName>Gus</firstName>
      </item>
      <item>
        <state>KS</state>
        <district>4</district>
        <party>R</party>
        <sponsorshipWithdrawnDate />
        <identifiers>
          <lisID>2022</lisID>
          <bioguideId>P000602</bioguideId>
          <gpoId>7952</gpoId>
        </identifiers>
        <middleName />
        <fullName>Rep. Pompeo, Mike [R-KS-4]</fullName>
        <bioguideId>P000602</bioguideId>
        <sponsorshipDate>2015-05-01</sponsorshipDate>
        <isOriginalCosponsor>False</isOriginalCosponsor>
        <lastName>Pompeo</lastName>
        <firstName>Mike</firstName>
      </item>
      <item>
        <state>IL</state>
        <district>16</district>
        <party>R</party>
        <sponsorshipWithdrawnDate />
        <identifiers>
          <lisID>2014</lisID>
          <bioguideId>K000378</bioguideId>
          <gpoId>7931</gpoId>
        </identifiers>
        <middleName />
        <fullName>Rep. Kinzinger, Adam [R-IL-16]</fullName>
        <bioguideId>K000378</bioguideId>
        <sponsorshipDate>2015-05-21</sponsorshipDate>
        <isOriginalCosponsor>False</isOriginalCosponsor>
        <lastName>Kinzinger</lastName>
        <firstName>Adam</firstName>
      </item>
      <item>
        <state>NC</state>
        <district>8</district>
        <party>R</party>
        <sponsorshipWithdrawnDate />
        <identifiers>
          <lisID>2140</lisID>
          <bioguideId>H001067</bioguideId>
          <gpoId />
        </identifiers>
        <middleName />
        <fullName>Rep. Hudson, Richard [R-NC-8]</fullName>
        <bioguideId>H001067</bioguideId>
        <sponsorshipDate>2015-11-05</sponsorshipDate>
        <isOriginalCosponsor>False</isOriginalCosponsor>
        <lastName>Hudson</lastName>
        <firstName>Richard</firstName>
      </item>
      <item>
        <state>NY</state>
        <district>27</district>
        <party>R</party>
        <sponsorshipWithdrawnDate />
        <identifiers>
          <bioguideId>C001092</bioguideId>
          <lisID>2151</lisID>
          <gpoId />
        </identifiers>
        <middleName />
        <fullName>Rep. Collins, Chris [R-NY-27]</fullName>
        <bioguideId>C001092</bioguideId>
        <sponsorshipDate>2015-11-19</sponsorshipDate>
        <isOriginalCosponsor>False</isOriginalCosponsor>
        <lastName>Collins</lastName>
        <firstName>Chris</firstName>
      </item>
    </cosponsors>
    <latestAction>
      <text>Referred to the Subcommittee on Health.</text>
      <actionDate>2015-03-27</actionDate>
      <links />
    </latestAction>
    <titles>
      <item>
        <chamberName />
        <chamberCode />
        <titleType>Short Titles as Introduced</titleType>
        <parentTitleType />
        <title>Generic Complex Drugs Safety and Effectiveness for Patients Act of 2015</title>
      </item>
      <item>
        <chamberName />
        <chamberCode />
        <titleType>Official Title as Introduced</titleType>
        <parentTitleType />
        <title>To require a study by the Government Accountability Office (GAO) to assess the Food and Drug Administration's current regulatory pathway for reviewing generic versions of nonbiologic complex drug products, and for other purposes.</title>
      </item>
      <item>
        <chamberName />
        <chamberCode />
        <titleType>Display Title</titleType>
        <parentTitleType />
        <title>Generic Complex Drugs Safety and Effectiveness for Patients Act of 2015</title>
      </item>
    </titles>
    <summaries>
      <billSummaries>
        <item>
          <lastSummaryUpdateDate>2015-08-14T17:41:11Z</lastSummaryUpdateDate>
          <actionDesc>Introduced in House</actionDesc>
          <versionCode>00</versionCode>
          <name>Introduced in House</name>
          <updateDate>2015-03-24T04:00:00Z</updateDate>
          <text><![CDATA[<p><b>Generic Complex Drugs Safety and Effectiveness for Patients Act of 2015</b></p> <p>This bill requires the Government Accountability Office (GAO) to study whether generic versions of certain complex drugs or certain biological drugs face significantly different challenges in meeting the approval standards of the Food and Drug Administration (FDA) than generic versions of small-molecule drugs. (Complex drugs and biological drugs can be composed of large molecules that are more difficult to fully characterize than small molecules, so it can be more difficult to demonstrate that generic versions of these drugs are the same as the brand name versions.)</p> If the GAO determines that these generic drugs face significantly different challenges, then the GAO must also determine: (1) the evidence that should be required to demonstrate that one of these generic drugs is sufficiently similar to the brand name drug in safety, composition, and activity; (2) whether the Federal Food, Drug, and Cosmetic Act should be amended to address the approval of these generic drugs; and (3) whether the FDA should develop a policy document on the evidence that is necessary to obtain approval of these generic drugs.]]></text>
          <actionDate>2015-03-24</actionDate>
        </item>
      </billSummaries>
    </summaries>
    <notes />
    <policyArea>
      <name>Health</name>
    </policyArea>
    <laws />
    <cboCostEstimates />
    <version>1.0.0</version>
    <originChamber>House</originChamber>
    <createDate>2015-03-25T08:45:43Z</createDate>
    <constitutionalAuthorityStatementText><![CDATA[<pre>[Congressional Record Volume 161, Number 49 (Tuesday, March 24, 2015)]From the Congressional Record Online through the Government Publishing Office [<a href='http://www.gpo.gov'>www.gpo.gov</a>]By Mr. BURGESS:H.R. 1576.Congress has the power to enact this legislation pursuantto the following:Article I, Section 8, Clause 1 of the United StatesConstitution, which grants Congress the power to lay andcollect taxes, duties, imposts and excises, to pay the debtsand provide for the common defense and general welfare of theUnited States.Article 1, Section 8, Clause 3, of the United StatesConstitution, which grants Congress the power to regulatecommerce with foreign nations, and among the several states,and with the Indian tribes.[Page H1901]</pre>]]></constitutionalAuthorityStatementText>
    <congress>114</congress>
    <amendments />
    <subjects>
      <billSubjects>
        <policyArea>
          <name>Health</name>
        </policyArea>
        <legislativeSubjects>
          <item>
            <name>Congressional oversight</name>
          </item>
          <item>
            <name>Drug safety, medical device, and laboratory regulation</name>
          </item>
          <item>
            <name>Government studies and investigations</name>
          </item>
          <item>
            <name>Prescription drugs</name>
          </item>
        </legislativeSubjects>
      </billSubjects>
    </subjects>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>

